Brief: Tvardi Therapeutics Announces First Quarter 2025 Results And Provides Business Update
13/05/2025 21:10
May 13 (Reuters) - Tvardi Therapeutics Inc TVRD.O: TVARDI THERAPEUTICS ANNOUNCES FIRST QUARTER 2025 RESULTS AND PROVIDES BUSINESS UPDATE TVARDI THERAPEUTICS: CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AT CLOSING ANTICIPATED TO BE SUFFICIENT TO FUND OPERATIONS INTO 2H 2026 TVARDI THERAPEUTICS: ON TRACK FOR MULTIPLE PHASE 2 DATA READOUTS WITH STAT3 INHIBITOR, TTI-101, WITH LEAD PROGRAM IN IPF EXPECTED IN 2H 2025 TVARDI THERAPEUTICS INC - COMPLETES MERGER WITH CARA THERAPEUTICS Source text: ID:nBwbjbZ6qa Further company coverage: TVRD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tvardi Therapeutics
See all newsTvardi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tvardi Therapeutics Q2 net loss slightly lower estimates
Brief: Tvardi Therapeutics Inc Q2 Net Income USD -6.5 Million Vs. IBES Estimate USD -6.54 Million
Tvardi Therapeutics, Inc. expected to post a loss of 70 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:50 PM